Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Historical Holders from Q1 2023 to Q3 2025

Symbol
ELVN on Nasdaq
CUSIP
29337E102
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
59.7M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
59.4M
Holdings value
$1.22B
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
131
Number of buys
76
Number of sells
-41
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13.4% $159M 7.92M ORBIMED ADVISORS LLC Jun 16, 2025
FMR LLC 13.3% $161M 7.87M FMR LLC Sep 30, 2025
Commodore Capital LP 9.9% $125M 6.02M Commodore Capital LP Jun 30, 2025
Fairmount Funds Management LLC 6.3% -4.29% $76.8M $10.5M 3.71M +15.9% Fairmount Funds Management LLC Jun 30, 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66M 3.23M Venrock Healthcare Capital Partners III, L.P. Sep 30, 2025
BlackRock, Inc. 5.1% $58.9M 2.94M BlackRock, Inc. Jun 30, 2025
Polar Capital Holdings Plc 5.17% +5.6% $52.5M $3.04M 2.54M +6.16% Polar Capital Holdings Plc Jun 30, 2025

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 59.4M $1.22B -$295K $20.47 131
2025 Q2 59.4M $1.19B +$192M $20.06 123
2025 Q1 49.9M $984M +$4.35M $19.68 118
2024 Q4 49.6M $1.12B +$24.8M $22.50 111
2024 Q3 47.7M $1.22B -$20.8M $25.54 100
2024 Q2 48.3M $1.13B +$91.7M $23.37 92
2024 Q1 44.5M $781M +$95.5M $17.59 72
2023 Q4 39M $540M -$1.28M $13.84 61
2023 Q3 39.1M $534M -$2.18M $13.66 61
2023 Q2 39.1M $798M +$113M $20.41 61
2023 Q1 33.6M $735M +$735M $21.90 44